Biofrontera INC. (BFRIW) — SEC Filings

Overview

Biofrontera INC. (BFRIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 5, 2025: Biofrontera Inc. (BFRIW) is offering 4,000,640 shares of common stock for resale by selling stockholders, converted from Series C Convertible Preferred Stock issued on October 24, 2025. The company will not receive any proceeds from this sale. Biofrontera's primary product, Ameluz®, a photodynamic t

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 43 neutral, 3 mixed. The dominant filing sentiment for Biofrontera INC. is neutral.

Filing Type Overview

Biofrontera INC. (BFRIW) has filed 4 S-1, 26 8-K, 5 10-Q, 1 S-1/A, 3 DEF 14A, 1 10-K, 7 SC 13G/A, 2 SC 13G, 1 8-K/A with the SEC between Apr 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Biofrontera Resale Offering Signals Strategic Shift, Ameluz® Rights Acquired — S-1 · Dec 5, 2025 Risk: high
  Biofrontera Inc. (BFRIW) is offering 4,000,640 shares of common stock for resale by selling stockholders, converted from Series C Convertible Preferred Stock is
• 8-K Filing — 8-K · Nov 13, 2025
• Biofrontera's Losses Widen Amid Strategic Shift, Liquidity Concerns — 10-Q · Nov 12, 2025 Risk: high
  Biofrontera Inc. reported a net loss of $6.649 million for the three months ended September 30, 2025, an increase from $5.669 million in the prior-year period.
• 8-K Filing — 8-K · Nov 10, 2025
• Biofrontera Inc. Files 8-K with Key Agreements and Acquisitions — 8-K · Nov 7, 2025 Risk: medium
  On November 6, 2025, Biofrontera Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement and completed a
• Biofrontera Inc. Completes Acquisition, Reports Equity Sales — 8-K · Oct 24, 2025 Risk: medium
  On October 20, 2025, Biofrontera Inc. reported the completion of an acquisition. The company also announced unregistered sales of equity securities and entered
• Biofrontera Inc. Files 8-K with Regulatory Disclosures — 8-K · Oct 23, 2025 Risk: low
  Biofrontera Inc. filed an 8-K on October 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Dela
• Biofrontera Inc. Files 8-K on Shareholder Vote Matters — 8-K · Sep 19, 2025 Risk: low
  Biofrontera Inc. filed an 8-K on September 19, 2025, reporting on matters submitted to a vote of security holders as of September 16, 2025. The filing details t
• Biofrontera Amends Ameluz Deal, Boosts Dosage, Divests Xepi — S-1/A · Aug 13, 2025 Risk: high
  Biofrontera Inc. (BFRIW) is a U.S.-based biopharmaceutical company focused on dermatological conditions, primarily photodynamic therapy (PDT) for actinic kerato
• Biofrontera Inc. Files 8-K: Director, Officer, and Compensation Updates — 8-K · Aug 11, 2025 Risk: low
  On August 11, 2025, Biofrontera Inc. filed an 8-K report detailing changes in its board of directors and officers, along with updates on compensatory arrangemen
• Biofrontera Seeks Reverse Split, Series C Conversion Approval — DEF 14A · Aug 5, 2025 Risk: high
  Biofrontera Inc. has filed a DEF 14A proxy statement for a Special Meeting of Stockholders on September 16, 2025, at 10:00 a.m. Eastern Time, to be held virtual
• Biofrontera Files S-1 for Continuous Offering, Signaling Capital Raise — S-1 · Jul 16, 2025 Risk: medium
  Biofrontera Inc. (BFRIW) filed an S-1 on July 16, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move to raise
• Biofrontera Inc. Files 8-K with Key Corporate Updates — 8-K · Jul 1, 2025 Risk: medium
  On June 27, 2025, Biofrontera Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, unregi
• Biofrontera Inc. Files 8-K with Financial Updates — 8-K · Jun 30, 2025 Risk: low
  Biofrontera Inc. filed an 8-K on June 30, 2025, reporting on financial statements and exhibits. The filing pertains to the company's operations as of the same d
• Biofrontera Inc. Files 8-K on Shareholder Votes — 8-K · Jun 18, 2025 Risk: low
  Biofrontera Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details the company
• Biofrontera Inc. Files 8-K Report — 8-K · Jun 11, 2025 Risk: low
  On June 11, 2025, Biofrontera Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material
• Biofrontera Inc. Files 8-K Report — 8-K · Jun 3, 2025 Risk: low
  On June 3, 2025, Biofrontera Inc. filed an 8-K report detailing other events and financial statements. The filing indicates the company's principal executive of
• Biofrontera Inc. Faces Delisting Concerns — 8-K · May 23, 2025 Risk: high
  Biofrontera Inc. filed an 8-K on May 23, 2025, reporting a notice of delisting or failure to meet continued listing standards as of May 21, 2025. The company, i
• Biofrontera Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Biofrontera Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of
• Biofrontera Inc. Faces Delisting Concerns — 8-K · May 14, 2025 Risk: high
  Biofrontera Inc. filed an 8-K on May 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest eve
• Biofrontera Inc. Files Definitive Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Biofrontera Inc. filed its definitive proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The company, headquartered in Woburn, MA,
• Biofrontera Inc. Changes Certifying Accountant — 8-K · Apr 18, 2025 Risk: low
  Biofrontera Inc. filed an 8-K on April 18, 2025, reporting a change in its certifying accountant as of April 17, 2025. The filing also includes financial statem
• Biofrontera Inc. Files 8-K on Financials — 8-K · Mar 21, 2025 Risk: low
  Biofrontera Inc. filed an 8-K report on March 21, 2025, detailing its results of operations and financial condition. The filing also includes financial statemen
• Biofrontera Inc. Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
  Biofrontera Inc. filed its 2024 10-K on March 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details its
• Biofrontera Inc. Files S-1 with SEC — S-1 · Jan 17, 2025 Risk: medium
  Biofrontera Inc. filed an S-1 form on January 21, 2025, detailing its financial status. The company, incorporated in Delaware with its principal office in Wobur
• Biofrontera Inc. Faces Delisting Notice, Enters New Agreement — 8-K · Nov 27, 2024 Risk: high
  On November 21, 2024, Biofrontera Inc. entered into a material definitive agreement related to a direct financial obligation. The company also issued a notice o
• Biofrontera Inc. Files 8-K Current Report — 8-K · Nov 22, 2024 Risk: low
  Biofrontera Inc. filed an 8-K on November 22, 2024, reporting on its current status. The filing primarily serves as a notification of events and includes financ
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Biofrontera Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: medium
  Biofrontera Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Key
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• Biofrontera Inc. Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  Biofrontera Inc. filed an 8-K report on November 13, 2024, to disclose information regarding its results of operations and financial condition, as well as finan
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• SC 13G/A Filing — SC 13G/A · Nov 1, 2024
• Biofrontera Inc. Files 8-K with Financials — 8-K · Oct 31, 2024 Risk: low
  Biofrontera Inc. filed an 8-K on October 31, 2024, reporting on its financial statements and exhibits. The filing details its corporate structure, including com
• SC 13G/A Filing — SC 13G/A · Oct 23, 2024
• Biofrontera Inc. Files 8-K Report — 8-K · Oct 7, 2024 Risk: low
  On October 7, 2024, Biofrontera Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No speci
• SC 13G Filing — SC 13G · Sep 12, 2024
• Biofrontera Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 14, 2024 Risk: medium
  Biofrontera Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter of
• Biofrontera Inc. Files 8-K Report — 8-K · Jun 24, 2024 Risk: low
  On June 24, 2024, Biofrontera Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specifi
• Biofrontera Inc. Announces Corporate Changes and Shareholder Vote — 8-K · Jun 14, 2024 Risk: medium
  Biofrontera Inc. announced on June 12, 2024, a series of significant corporate actions. These include the departure of certain directors and officers, the elect
• SC 13G/A Filing — SC 13G/A · May 29, 2024
• Biofrontera Inc. Files 8-K for Other Events — 8-K · May 22, 2024 Risk: medium
  On May 17, 2024, Biofrontera Inc. filed an 8-K report detailing an event that occurred on the same date. The filing pertains to "Other Events" and was submitted
• Biofrontera Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk:
  Biofrontera Inc. (BFRIW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Biofrontera Inc. filed a 10-Q report for the quarterly period ended March
• SC 13G Filing — SC 13G · May 7, 2024
• Biofrontera Inc. Files S-1 Registration Statement — S-1 · May 3, 2024 Risk: low
  Biofrontera Inc. (BFRIW) filed a IPO Registration (S-1) with the SEC on May 3, 2024. Biofrontera Inc. filed an S-1 registration statement with the SEC on May 3,
• Biofrontera Inc. Files 8-K with Corporate Amendments — 8-K · Apr 30, 2024 Risk: low
  On April 25, 2024, Biofrontera Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and the filing of financial statements and exhibit
• Biofrontera Inc. Files 8-K on Shareholder Vote Matters — 8-K · Apr 25, 2024 Risk: low
  Biofrontera Inc. filed an 8-K on April 25, 2024, reporting on matters submitted to a vote of its security holders on April 24, 2024. The filing details the comp
• Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders on June 12, 2024 — DEF 14A · Apr 17, 2024 Risk: low
  Biofrontera Inc. (BFRIW) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. The 2024 Annual Meeting of Stockholders for Biofrontera Inc. will be
• Biofrontera Inc. Files 8-K/A Amendment — 8-K/A · Apr 3, 2024 Risk: low
  Biofrontera Inc. filed an amendment (8-K/A) on April 3, 2024, to a previous report dated March 26, 2024. The amendment pertains to 'Other Events' and does not s

Risk Profile

Risk Assessment: Of BFRIW's 38 recent filings, 7 were flagged as high-risk, 11 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Biofrontera INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $6.988M
• Net Income: -$6.649M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $3.417M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Prof. Hermann Luebbert
• Stephen E. Older, Esq.
• Andrew J. Terjesen, Esq.
• Daniel Hakansson
• Board of Directors
• Prof. Dr. Hermann Luebbert

Industry Context

Biofrontera operates in the dermatology market, specifically focusing on photodynamic therapy (PDT) for actinic keratoses (AK). The AK treatment market is substantial, with an estimated 58 million Americans affected. While PDT currently holds a small market share (2%), Biofrontera aims to expand this by targeting a larger market size of $500 million, encompassing current PDT users and a portion of the cryotherapy market. Competition exists from other pharmaceutical companies and existing treatments.

Top Tags

corporate-governance (6) · sec-filing (6) · disclosure (5) · financials (5) · filing (5) · 8-k (5) · shareholder-vote (4) · financial-reporting (4) · 10-Q (4) · Biopharmaceutical (3)

Key Numbers

• Shares of Common Stock: 4,000,640 — Offered for resale by Selling Stockholders, converted from Series C Preferred Stock.
• Last Reported Sale Price: $0.81 — Per share of common stock on December 2, 2025, indicating low valuation.
• Earnout Percentage: 12% — Of US Ameluz® revenues when net sales are $65.0 million or less, payable to Biofrontera Group.
• Maximum Purchase Price: $10,000,000 — For the divestiture of the Xepi® product line to Pelthos Therapeutics Inc.
• Cash Payment: $3,000,000 — Received on the Closing Date for the Xepi® Transaction.
• Clearance Rate: 91% — Of AKs after one or two Ameluz® PDT treatments.
• Americans Affected: 58,000,000 — By Actinic Keratoses (AKs).
• PDT Market Share: 2% — Current market share for Photodynamic Therapy in the AK treatment market.
• Targeted Market Size: $500,000,000 — For Ameluz® PDT, combining current PDT market and a portion of cryotherapy market.
• Net Loss (Q3 2025): $6.649M — Increased from $5.669M in Q3 2024
• Net Loss (9M 2025): $16.176M — Slightly improved from $16.363M in 9M 2024
• Total Revenues, Net (Q3 2025): $6.988M — Decreased from $9.012M in Q3 2024
• Total Revenues, Net (9M 2025): $24.605M — Relatively flat compared to $24.762M in 9M 2024
• Cash Flows Used in Operating Activities (9M 2025): $10.985M — Increased from $9.253M in 9M 2024
• Accumulated Deficit: $133.585M — As of September 30, 2025, indicating significant historical losses

Related Companies

BFRI

Frequently Asked Questions